HbA 1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
CONCLUSIONSDulaglutide 1.5-mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.
Source: Diabetes Care - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Incretin Therapy | Statistics